Core Viewpoint - The strategic partnership between Meili Tianyuan Medical Health and Shiseido China aims to enhance the high-end brand ecosystem and improve service customization in the beauty and skincare market [1][3]. Company Overview - Meili Tianyuan operates over 734 stores across 20 first-tier and new first-tier cities in China, serving more than one million customers annually, primarily high-income women [3]. - The company has experienced significant growth, with a projected revenue of at least 3 billion yuan for 2025, representing a year-on-year increase of no less than 16% [4]. Strategic Partnership - Meili Tianyuan will serve as the exclusive launch platform for Shiseido's RQ PYOLOGY brand in high-end beauty salons, integrating RQ PYOLOGY's products and services into its store network [1][3]. - The collaboration aims to connect medical beauty recovery with daily skincare, aligning with Meili Tianyuan's "dual beauty" strategy of integrating lifestyle and medical beauty [3][4]. Financial Performance - The company anticipates adjusted net profits of at least 380 million yuan for 2025, reflecting a year-on-year growth of no less than 40% [4]. - The acquisition of the second-largest beauty chain, Nairui, has contributed to a significant increase in net profit margins, from 6.5% pre-acquisition to 10.4% in the first half of 2025 [5]. Industry Context - The domestic high-end beauty and medical beauty market is undergoing structural adjustments, with a shift towards systematic and scientific skincare services [6]. - The partnership reflects a shared understanding of the trend towards enhanced service experiences and professional endorsements in the high-end female consumer market [6].

Core Viewpoint - Marubi Biological Technology Co., Ltd. has shown strong financial performance in Q1 2024, with significant year-on-year growth in both revenue and net profit, indicating a robust business strategy and market position [1][2]. Financial Performance - In Q1 2024, the company achieved total revenue of 847 million yuan, a year-on-year increase of 28.01%, and a net profit attributable to shareholders of 135 million yuan, up 22.07% [1]. - For the full year 2024, the company projects revenue of 2.97 billion yuan, representing a 33.44% increase, and a net profit of 342 million yuan, which is a 31.69% growth [1]. Brand Strategy - The company is deepening its "big product" strategy for the Marubi brand, focusing on "eye care + wrinkle reduction," with the upgraded peptide eye cream achieving online GMV sales of 533 million yuan, a 146% increase [2]. - The PL brand is enhancing user engagement through product innovation, launching summer products tailored for specific skin needs, and achieving over 100 million yuan in GMV sales for a limited series [2]. Market Trends - The Chinese beauty industry is experiencing rapid growth, with increasing competition and diverse consumer demands, necessitating higher quality and value-added products [2]. - The market for recombinant collagen products is projected to grow from 18.5 billion yuan in 2022 to 108.3 billion yuan by 2027, with a compound annual growth rate of 42.4% [3]. Technological Advancements - The company emphasizes biotechnology as a crucial aspect of its current and future operations, particularly in the development of functional proteins and recombinant collagen technology [3]. - Marubi has transitioned from being a "whistleblower" to a standard setter in the industry, reflecting its leadership role in formulating national standards for recombinant collagen [2]. Investment Strategy - The company has established multiple investment funds targeting the beauty and medical aesthetics industries, aligning with its "dual beauty" strategy [3]. - Analysts note that Marubi has successfully restructured its products and channels, with upward brand momentum and significant growth potential in its flagship products [3].